In primary tumor samples, 67% of tumors overexpressed the ERBB2 gene, including breast carcinoma, cholangiocarcinoma, hepatocellular carcinoma, cervical squamous cell carcinoma, lung adenocarcinoma, bladder carcinoma, pancreatic adenocarcinoma, lung squamous cell carcinoma, stomach adenocarcinoma, uterine corpus endometrial carcinoma, thyroid cancer, esophageal carcinoma, and rectum adenocarcinoma (Figure S1A). This evidence concerns the gene ERBB2 and uterine corpus endometrial carcinoma.